General Atlantic, L.P. holds a concentrated book of 12 stocks worth $2.1B as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they trimmed XP Inc - Class A. Their largest long position is Dlocal Ltd at 28% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1017645/holdings"
Use Arkolith to show GENERAL ATLANTIC, L.P.'s latest holdings, largest changes, and filing provenance.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
96% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Dlocal CL A | $605.1M | 46.66M | 28.2% | —Held | |
| 2 | CHIME CL A | $398.2M | 21.26M | 18.5% | —Held | |
| 3 | XP, Inc CL A | $391.6M | 20.57M | 18.2% | ▼−9.4% Reduced · −2.1M sh | |
| 4 | Alkami COM | $240.3M | 15.34M | 11.2% | ▲+28% Added · +3.3M sh | |
| 5 | Pharvaris COM | $226.9M | 8.03M | 10.6% | —Held | |
| 6 | European Wax Center CL A | $75.8M | 13.11M | 3.5% | —Held | |
| 7 | Revolution Medicines COM | $68.8M | 707.8K | 3.2% | ▼−75% Reduced · −2.1M sh | |
| 8 | Nurix Therapeutics COM | $63.6M | 4.10M | 3.0% | ▼−16% Reduced · −795K sh | |
| 9 | Centessa Pharmaceuticals ADS | $53.8M | 1.35M | 2.5% | ▼−78% Reduced · −4.8M sh | |
| 10 | Riskified CL A | $20.9M | 5.32M | 1.0% | —Held | |
| 11 | Grove Collaborative CL A | $3.2M | 2.47M | 0.1% | —Held | |
| 12 | Webull ORD SHS | $244K | 50.8K | 0.0% | —Held |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 12 | $2.1B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 13 | $2.9B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 13, 2025 | 16 | $3.3B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 15 | $3.6B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 14, 2025 | 15 | $3.0B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 7, 2025 | 16 | $2.8B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 12, 2024 | 18 | $3.5B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 19 | $3.2B | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 22 | $4.3B | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 13, 2024 | 26 | $7.0B | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 29 | $6.5B | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 11, 2023 | 30 | $6.3B | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 31 | $8.6B | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 33 | $7.6B | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 39 | $8.5B | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 12, 2022 | 38 | $7.7B | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 16, 2022 | 35 | $10.9B | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 11, 2022 | 32 | $13.0B | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 15, 2021 | 25 | $17.1B | 13F-HR |
| Q2 2021 | Jun 30, 2021 | Aug 13, 2021 | 17 | $14.1B | 13F-HR |
| Q1 2021 | Mar 31, 2021 | May 17, 2021 | 12 | $8.5B | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 12, 2021 | 9 | $7.7B | 13F-HR |
| Q3 2020 | Sep 30, 2020 | Nov 13, 2020 | 7 | $6.5B | 13F-HR |
| Q2 2020 | Jun 30, 2020 | Aug 13, 2020 | 7 | $3.3B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.